Use of physiologically based pharmacokinetic models to evaluate the impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone

Journal of Pharmaceutical Sciences

Volumn 101, Issue 3, 2012, Pages 1281-1301

  Wu, Baojian ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

ABC transporters; Glucuronidation; Hepatic metabolism; Intestinal bacteria; Intestinal metabolism; Pharmacokinetics; UGTs

Indexed keywords

AGLYCONE; GLUCURONIDE;

AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL MODEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; GLUCURONIDATION; HYDROLYSIS; METABOLIC CLEARANCE RATE;

EID: 84855900973     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22827     Document Type: Article

References (26)

1. Beutler E, Gelbart T, Demina A. 1998. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170-8174.
2. Wu B, Kulkarni K, Basu S, Zhang S, Hu M. 2011. First-pass metabolism via UDP-glucuronosyltransferase: A barrier to oral bioavailability of phenolics. J Pharm Sci 100(9):3655-3681.
3. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW. 2005. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15(10):677-685.
4. Kosaka K, Sakai N, Endo Y, Fukuhara Y, Tsuda-Tsukimoto M, Ohtsuka T, Kino I, Tanimoto T, Takeba N, Takahashi M, Kume T. 2011. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab Dispos 39(9):1495-1502.
5. Cubitt HE, Houston JB, Galetin A. 2009. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance. Pharm Res 26(5):1073-1083.
6. Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A. 2009. Prediction of drug clearance by glucuronidation from in vitro data: Use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37(1):82-89.
7. Jeong EJ, Liu X, Jia X, Chen J, Hu M. 2005. Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions. Curr Drug Metab 6(5):455-468.
8. Liu Z, Hu M. 2007. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol 3(3):389-406.
9. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S, Redinbo MR. 2010. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330(6005):831-835.
10. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KL. 2006. Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27(5):447-486.
11. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KL. 2006. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther 319(1):459-467.
12. Lee JK, Abe K, Bridges AS, Patel NJ, Raub TJ, Pollack GM, Brouwer KL. 2009. Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver. Drug Metab Dispos 37(9):1916-1921.
13. Xu H, Kulkarni KH, Singh R, Yang Z, Wang SW, Tam VH, Hu M. 2009. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm 6(6):1703-1715.
14. Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, Siegmund W. 2006. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J Pharmacol Exp Ther 318:1293-1299.
15. Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, Borst P. 2005. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA 102(20):7274-7279.
16. Horikawa M, Kato Y, Sugiyama Y. 2002. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res 19:1345-1353.
17. Cong D, Doherty M, Pang KS. 2000. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab Dispos 28(2):224-235.
18. Pang KS, Durk MR. 2010. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn 37(6):591-615.
19. Fan J, Chen S, Chow EC, Pang KS. 2010. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 11(9):743-761.
20. Tam D, Tirona RG, Pang KS. 2003. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 31(4):373-383.
21. Sun H, Pang KS. 2010. Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res 27(7):1237-1254.
22. Schlosser PM, Borghoff SJ, Coldham NG, David JA, Ghosh SK. 2006. Physiologically-based pharmacokinetic modeling of genistein in rats, Part I: Model development. Risk Anal 26(2):483-500.
23. Sun H, Pang KS. 2009. Disparity in intestine disposition between formed and preformed metabolites and implications: A theoretical study. Drug Metab Dispos 37(1):187-202.
24. Endres CJ, Endres MG, Unadkat JD. 2009. Interplay of drug metabolism and transport: A real phenomenon or an artifact of the site of measurement? Mol Pharm 6(6):1756-1765.
25. Sun H, Zeng YY, Pang KS. 2010. Interplay of phase II enzymes and transporters in futile cycling: Influence of multidrug resistance-associated protein 2-mediated excretion of estradiol 17beta-D-glucuronide and its 3-sulfate metabolite on net sulfation in perfused TR(-) and Wistar rat liver preparations. Drug Metab Dispos 38(5):769-780.
26. Moon YJ, Sagawa K, Frederick K, Zhang S, Morris ME. 2006. Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS J 8(3):E433-E442.